AptaBio Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
AptaBio Therapeutics has a total shareholder equity of ₩49.0B and total debt of ₩13.4B, which brings its debt-to-equity ratio to 27.3%. Its total assets and total liabilities are ₩83.3B and ₩34.4B respectively.
Key information
27.3%
Debt to equity ratio
₩13.38b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩37.98b |
| Equity | ₩48.97b |
| Total liabilities | ₩34.36b |
| Total assets | ₩83.32b |
Recent financial health updates
AptaBio Therapeutics (KOSDAQ:293780) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Oct 29
Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?
Jul 12Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money
Mar 26Companies Like AptaBio Therapeutics (KOSDAQ:293780) Can Afford To Invest In Growth
Jan 01
Recent updates
AptaBio Therapeutics (KOSDAQ:293780) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Oct 29Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?
Jul 12Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money
Mar 26Do Institutions Own AptaBio Therapeutics Inc. (KOSDAQ:293780) Shares?
Feb 23Companies Like AptaBio Therapeutics (KOSDAQ:293780) Can Afford To Invest In Growth
Jan 01Financial Position Analysis
Short Term Liabilities: A293780's short term assets (₩43.5B) exceed its short term liabilities (₩17.4B).
Long Term Liabilities: A293780's short term assets (₩43.5B) exceed its long term liabilities (₩17.0B).
Debt to Equity History and Analysis
Debt Level: A293780 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A293780's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A293780 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A293780 has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 44.7% each year.